Clinical Trial

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Name: A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) — clinical trial record (NCT07465835)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.

Protocol Amendment History 1 change

notable Trial sites expanded: 1 -> 4 locations 2026-05-21

Trial Details

NCT Number	NCT07465835
Lead Sponsor	Electra Therapeutics Inc.
Conditions	T Cell Malignancies
Enrollment	84 participants
Start Date	2026-02-17
Primary Completion	2028-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-07-08